Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
02/2014
02/18/2014CA2635381C Hemostatic material
02/18/2014CA2634394C Homogeneous paste formulations
02/18/2014CA2624492C Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
02/18/2014CA2624105C Phenyl-[1,2,4]-oxadiazol-5-one derivatives with phenyl group, processes for their preparation and their use as pharmaceuticals
02/18/2014CA2623250C Fluorinated compounds
02/18/2014CA2622523C Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
02/18/2014CA2611715C Methods and systems for neural maintenance and regeneration
02/18/2014CA2607486C Production of glucosamine from plant species
02/18/2014CA2607360C Solid dosage formulations of narcotic drugs having improved buccal adsorption
02/18/2014CA2600757C Pyrrolidine derivatives as histamine h3 receptor antagonists
02/18/2014CA2594377C 1h-indole-3-carboxylic acid derivatives and their use as ppar agonists
02/18/2014CA2593768C Use of .omega.3 unsaturated fatty acids for relieving lipotoxicity
02/18/2014CA2587805C Improved vitamin d content uniformity in pharmaceutical dosage forms
02/18/2014CA2577061C Histamine h3 receptor agents, preparation and therapeutic uses
02/18/2014CA2573484C Plant compositions enriched in dehydrosoyasaponin i (d-i) and methods of producing such compositions
02/18/2014CA2570213C Alpha-helical mimetics
02/18/2014CA2567495C Methods for treating bleeding disorders using sulfated polysaccharides
02/18/2014CA2564076C Chemical linkers and conjugates thereof
02/18/2014CA2563831C Monocyclic heterocycles as kinase inhibitors
02/18/2014CA2540459C Benzimidazole compounds and uses in treating proliferative disorders
02/18/2014CA2519773C Lipid-improving agent and composition containing lipid-improving agent
02/18/2014CA2500742C Compositions of fgf-18 and hyaluronic acid for stimulating cartilage production and treating osteoarthritis
02/18/2014CA2454756C Methods and compounds for the targeting of protein to exosomes
02/18/2014CA2429814C Rna interference mediating small rna molecules
02/18/2014CA2331923C Nucleic sequence and deduced protein sequence family with human endogenous retroviral motifs, and their uses
02/17/2014DE212013000010U1 Pharmazeutische Zusammensetzung für die Leber-Regeneration A pharmaceutical composition for liver regeneration
02/13/2014WO2014026198A1 Inhibitors of protein methyltransferase dot1l and methods of use thereof
02/13/2014WO2014026164A1 Compositions for preventing or slowing myelin deterioration or loss and for promoting myelin repair and method of making and using the same
02/13/2014WO2014026161A1 Vitamin supplement compositions for injection
02/13/2014WO2014026143A1 Conjugated anti-microbial compounds and conjugated anti-cancer compounds and uses thereof
02/13/2014WO2014026125A1 Pyrazine derivatives as fgfr inhibitors
02/13/2014WO2014026121A1 Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries
02/13/2014WO2014026081A1 Plant extracts for improving cognitive health and function
02/13/2014WO2014026077A1 Method for the treatment of acne
02/13/2014WO2014026073A1 Compositions with increased stability for inhibiting transient receptor potential ion channel trpa1
02/13/2014WO2014026039A2 Aryl-and heteroaryl-substituted benzene derivatives as modulators of pi3-kinase signalling pathways
02/13/2014WO2014026013A2 Methods for maintaining or improving health, well-being and/or a physiological function in a subject
02/13/2014WO2014025994A1 Antimicrobial compositions comprising glyceryl nitrates
02/13/2014WO2014025993A1 Inhibitors of d-amino acid oxidase
02/13/2014WO2014025989A1 Compositions and methods for treating mood disorders or skin disease or damage
02/13/2014WO2014025960A1 Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
02/13/2014WO2014025958A2 Treatment of immune-related and inflammatory diseases
02/13/2014WO2014025942A1 Nmda receptor modulators and uses related thereto
02/13/2014WO2014025905A1 Multi-component formulation for improving neurological function
02/13/2014WO2014025891A1 Neprilysin inhibitors
02/13/2014WO2014025890A1 Drug delivery vehicle comprising conjugates between targeting polyamino acids and fatty acids
02/13/2014WO2014025864A2 Methods of treating polycystic ovarian syndrome using chlorogenic acid
02/13/2014WO2014025854A1 Piperidine amide derivatives as hiv attachment inhibitors
02/13/2014WO2014025852A1 Tricyclic alkene derivatives as hiv attachment inhibitors
02/13/2014WO2014025850A1 Tricyclic amidine derivatives as hiv attachment inhibitors
02/13/2014WO2014025842A1 Treatment of helicobacter pylori infections
02/13/2014WO2014025837A1 Methods for treatment and prevention of tauopathies by inhibiting endothelin receptors
02/13/2014WO2014025814A1 Treatment regimens
02/13/2014WO2014025808A1 Curcumin analogs
02/13/2014WO2014025807A1 Pharmaceutical compositions comprising l-leucovorin
02/13/2014WO2014025805A1 Carbohydrate conjugated rna agents and process for their preparation
02/13/2014WO2014025795A1 Compositions for the delivery of rna and drugs into cells
02/13/2014WO2014025785A2 Prion protein ligands as therapeutic agents for neurodegenerative disorders
02/13/2014WO2014025761A1 Methods to treat neurodegenerative diseases
02/13/2014WO2014025759A1 Iap antagonists
02/13/2014WO2014025749A2 Small molecule inhibitors of viral protein interactions with human t-rna
02/13/2014WO2014025736A1 Hcv ns3 protease inhibitors
02/13/2014WO2014025709A1 Compounds that are s1p modulating agents and/or atx modulating agents
02/13/2014WO2014025708A1 Compounds that are s1p modulating agents and/or atx modulating agents
02/13/2014WO2014025688A1 Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
02/13/2014WO2014025679A1 Process for the preparation of c-fms kinase inhibitors
02/13/2014WO2014025672A1 Water-soluble lipophilic natural compound formulations
02/13/2014WO2014025658A1 Pyrrolidine thrombin inhibitors
02/13/2014WO2014025651A1 Chroman derivatives as trpm8 inhibitors
02/13/2014WO2014025638A1 Pramipexole transdermal delivery for severe headaches
02/13/2014WO2014025593A1 Extended-release levetiracetam and method of preparation
02/13/2014WO2014025486A1 Novel pyrrolopyrimidine compounds as inhibitors of protein kinases
02/13/2014WO2014025406A1 Dental materials and method of manufacture
02/13/2014WO2014025395A1 Compounds and methods for targeting hsp90
02/13/2014WO2014025370A1 Tricyclic energy quencher compounds for reducing singlet oxygen generation
02/13/2014WO2014025365A1 Eyelid treatment
02/13/2014WO2014025314A1 An Antifungal Compound
02/13/2014WO2014025290A1 External therapy remedy for patients with atopic dermatitis
02/13/2014WO2014025206A1 Fast-dissolving oral film preparation comprising aripiprazole
02/13/2014WO2014025191A1 Novel tetrazolo hydrazine derivatives and pharmaceutical composition comprising same as active ingredient for preventing or treating cancer
02/13/2014WO2014025148A1 Cistanche tubulosa and fucoidan extract having effects of preventing hair loss and promoting hair growth, and method for producing same
02/13/2014WO2014025128A1 N2,n4-bis(4-(piperazine-1-yl)phenyl)pirimidine-2,4-diamine derivative or pharmaceutically acceptable salt thereof, and composition containing same as active ingredient for preventing or treating cancer
02/13/2014WO2014025042A1 Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same
02/13/2014WO2014025019A1 Animal feed and stress reducer for industrial animals
02/13/2014WO2014024993A1 Piperazine derivative and use thereof
02/13/2014WO2014024950A1 Method for producing 1,4-benzoxazine compound
02/13/2014WO2014024896A1 Adhesive patch agent containing agomelatine
02/13/2014WO2014024820A1 Pharmaceutical composition for treating new chronic kidney disease and method for screening medicine for new chronic kidney disease
02/13/2014WO2014024518A1 Filaggrin gene expression promoter
02/13/2014WO2014024268A1 Medicine
02/13/2014WO2014024210A2 Novel polymorphs of doxercalciferol
02/13/2014WO2014024202A1 An improved process for the preparation of memantine hydrochloride
02/13/2014WO2014024195A1 A3 adenosine receptor ligands for use in treatment of a sexual dysfunction
02/13/2014WO2014024168A1 Polymeric crown ether derivatives used in the treatment of proliferative diseases, in particular cancer
02/13/2014WO2014024164A1 Process for the preparation of pemetrexed and lysin salt thereof
02/13/2014WO2014024136A1 A method of managing diabetic foot ulcers, pressure ulcers, venous leg ulcers and associated complication
02/13/2014WO2014024125A1 Pyrazolo[4,3-d]pyrimidin-7(6h)-one derivatives as pde9 inhibitors
02/13/2014WO2014024119A1 Heterocyclic amides as itk inhibitors
02/13/2014WO2014024077A1 5-(1H-PYRAZOL-4-YL)-1H-PYRROLO[2,3-b]PYRIDINE DERIVATIVES AS KINASE INHIBITORS
02/13/2014WO2014024056A1 Pyrrolidine derivatives with antibacterial properties
1 ... 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 ... 7860